查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1957527

2026年全球寡核苷酸療法市場報告

Oligonucleotide Therapy Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，寡核苷酸療法市場發展迅速。預計該市場將從2025年的62億美元成長到2026年的69.1億美元，複合年成長率（CAGR）為11.5%。過去幾年的成長主要歸功於寡核苷酸合成領域研發的加強、標靶治療需求的成長、分子生物學技術的進步、慢性病和遺傳性疾病的增加，以及反義寡核苷酸和適配體技術的早期應用。

預計未來幾年寡核苷酸療法市場將快速成長，到2030年將達到108.7億美元，複合年成長率（CAGR）為12.0%。預測期內的成長要素包括個人化醫療的擴展、人工智慧（AI）在藥物研發中的應用、精準醫療舉措的推進、新一代遞送平台的開發以及生物技術公司與製藥公司之間合作的加強。預測期內的關鍵趨勢包括標靶基因調控、基於RNA干擾（RNAi）的治療方法、個人化醫療的發展、先進的藥物傳遞系統以及基於核酸的診斷技術。

政府支持醫療領域研發的各項措施預計將推動寡核苷酸療法市場的成長。這些措施包括政府機構在地方、區域、國家和國際層面實施的項目、政策和計劃，旨在應對特定的醫療挑戰、實現目標並促進社會變革。多個國家的政府正在採取措施支持寡核苷酸療法的各個方面。例如，根據美國醫學會（AMA）——一家總部位於美國的專業組織——的數據顯示，截至2025年4月，美國醫療保健支出在2023年達到4.9兆美元（人均14,570美元），比上年成長7.5%，超過了2022年4.6%的增幅。因此，政府主導的醫療研發投資正在推動寡核苷酸療法市場的成長。

寡核苷酸療法市場的主要企業正在開發先進治療方法，例如基因療法，旨在解決遺傳疾病的根本原因，改善患者預後，並減輕長期治療負擔。基因療法是治療方法。例如，2023年6月，美國生物技術公司Sarepta Therapeutics Inc.的ELEVIDYS獲得FDA核准，這是全球首個用於治療Duchenne氏肌肉失養症（DMD）兒童的基因治療藥物。這種單劑量療法旨在透過將編碼縮短的功能性肌肉營養不良蛋白的基因導入兒童細胞來阻止或逆轉疾病進展。

目錄

第1章：執行摘要

第2章 市場特徵

  • 市場定義和範圍
  • 市場區隔
  • 主要產品和服務概述
  • 全球寡核苷酸療法市場：吸引力評分及分析
  • 成長可能性分析、競合評価、戦略適合性評価、リスクプロファイル評価

第3章 市場供應鏈分析

  • 供應鏈與生態系概述
  • 清單：主要原料、資源和供應商
  • 主要經銷商和通路合作夥伴名單
  • 主要最終用戶列表

第4章：全球市場趨勢與策略

  • 關鍵科技與未來趨勢
    • 生物技術、基因組學和精準醫療
    • 數位化、雲端運算、巨量資料、網路安全
    • 工業4.0和智慧製造
    • 人工智慧（AI）和自主人工智慧
    • 物聯網、智慧基礎設施、互聯生態系統
  • 主要趨勢
    • 標靶基因調控
    • 基於RNA干擾的治療方法
    • 個性化醫療的發展
    • 先進的藥物傳輸系統
    • 基於核酸的診斷

第5章 終端用戶產業市場分析

  • 醫院
  • 研究機構
  • 製藥公司
  • 生技公司
  • 學術機構

第6章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅的影響、關稅戰和貿易保護主義對供應鏈的影響，以及 COVID-19 疫情對市場的影響。

第7章：全球策略分析架構、目前市場規模、市場對比及成長率分析

  • 全球寡核苷酸療法市場：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 全球寡核苷酸療法市場規模、對比及成長率分析
  • 全球寡核苷酸療法市場表現：規模與成長，2020-2025年
  • 全球寡核苷酸療法市場預測：規模與成長，2025-2030年，2035年預測

第8章：全球市場總規模（TAM）

第9章 市場細分

  • 按類型
  • 反義寡核苷酸、適體和其他類型
  • 透過使用
  • 感染疾病、腫瘤、神經退化性疾病、心血管疾病、腎臟疾病和其他最終用戶
  • 最終用戶
  • 醫院、研究機構
  • 按類型細分：反義寡核苷酸
  • RNA標靶反義寡核苷酸、DNA標靶反義寡核苷酸、化學修飾的反義寡核苷酸
  • 按類型細分：適體
  • DNA適體、RNA適體、低分子量適體
  • 按類型細分：其他類型
  • siRNA（小干擾RNA）、miRNA（微型RNA）、DNA酶和核糖酶、用於基因編輯的合成寡核苷酸

第10章 區域與國別分析

  • 全球寡核苷酸療法市場：按地區分類，實際結果和預測，2020-2025年，2025-2030年預測，2035年預測
  • 全球寡核苷酸療法市場：按國家/地區分類，實際結果和預測，2020-2025 年、2025-2030 年預測、2035 年預測

第11章 亞太市場

第12章：中國市場

第13章：印度市場

第14章：日本市場

第15章：澳洲市場

第16章：印尼市場

第17章：韓國市場

第18章 台灣市場

第19章 東南亞市場

第20章 西歐市場

第21章英國市場

第22章：德國市場

第23章：法國市場

第24章：義大利市場

第25章：西班牙市場

第26章：東歐市場

第27章：俄羅斯市場

第28章 北美市場

第29章：美國市場

第30章：加拿大市場

第31章：南美市場

第32章：巴西市場

第33章 中東市場

第34章：非洲市場

第35章 市場監理與投資環境

第36章：競爭格局與公司概況

  • 寡核苷酸療法市場：競爭格局及市場佔有率（2024年）
  • 寡核苷酸療法市場：公司評估矩陣
  • 寡核苷酸療法市場：公司概況
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Gilead Sciences Inc.
    • Biogen Inc.
    • Alnylam Pharmaceuticals Inc.

第37章 其他大型企業和創新企業

  • Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Avidity Biosciences Inc., Miragen Therapeutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies BV

第38章 世界の市場競合ベンチマーキングとダッシュボード

第39章 重大併購

第40章：高潛力市場國家、細分市場與策略

  • 2030年寡核苷酸療法市場：提供新機會的國家
  • 2030年寡核苷酸療法市場：蘊藏新機會的細分市場
  • オリゴヌクレオチド治療市場2030：成長戦略
    • 基於市場趨勢的策略
    • 競爭對手的策略

第41章附錄

簡介目錄
Product Code: PH3MOTHE02_G26Q1

Oligonucleotide therapy is a term for advanced molecular-targeting treatments that use chemically synthesized oligonucleotides with single-stranded DNA or RNA backbones, offering high selectivity. Oligonucleotides are designed to base-pair with specific DNA or RNA strands for most applications, with PCR primers being the most common use of oligonucleotides (polymerase chain reaction).

The main types of oligonucleotide therapy include antisense oligonucleotides, aptamers, and others. Antisense oligonucleotides (ASOs) are synthetic DNA oligomers that bind to a target RNA in a sequence-specific manner. They are used to inhibit gene expression, modify precursor messenger RNA splicing, and inactivate microRNAs. Oligonucleotide therapies are applied in infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases, and other conditions, and are utilized in hospitals and research institutes.

Tariffs have affected the oligonucleotide therapy market by increasing costs of imported nucleotides, reagents, and specialized synthesis equipment, causing delays in production and supply chains. The impact is particularly notable in segments such as antisense oligonucleotides and aptamers, with North America, Europe, and Asia-Pacific being most affected due to high import dependencies. Some positive impacts include incentivizing local manufacturing and fostering innovation in cost-effective oligonucleotide synthesis and delivery solutions.

The oligonucleotide therapy market research report is one of a series of new reports from The Business Research Company that provides oligonucleotide therapy market statistics, including oligonucleotide therapy industry global market size, regional shares, competitors with a oligonucleotide therapy market share, detailed oligonucleotide therapy market segments, market trends and opportunities, and any further data you may need to thrive in the oligonucleotide therapy industry. This oligonucleotide therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oligonucleotide therapy market size has grown rapidly in recent years. It will grow from $6.2 billion in 2025 to $6.91 billion in 2026 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to increasing r&d in oligonucleotide synthesis, growing demand for targeted therapies, advances in molecular biology techniques, rise in chronic and genetic diseases, early adoption of antisense and aptamer technologies.

The oligonucleotide therapy market size is expected to see rapid growth in the next few years. It will grow to $10.87 billion in 2030 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to expansion of personalized medicine, integration of ai in drug discovery, growth of precision medicine initiatives, development of next-gen delivery platforms, increasing partnerships between biotech and pharma companies. Major trends in the forecast period include targeted gene regulation, rna interference-based therapeutics, personalized medicine development, advanced drug delivery systems, nucleic acid-based diagnostics.

Government initiatives supporting research and development in healthcare are expected to drive growth in the oligonucleotide therapy market. Such initiatives encompass programs, policies, and projects undertaken by government authorities at local, regional, national, or international levels to address specific healthcare challenges, achieve objectives, and promote positive societal change. Several governments are implementing initiatives that support various aspects of oligonucleotide therapy. For instance, in April 2025, according to the American Medical Association, a US-based professional organization, U.S. health spending in 2023 rose by 7.5% to $4.9 trillion, or $14,570 per capita, surpassing the 4.6% increase seen in 2022. These government-led investments in healthcare research and development are therefore driving growth in the oligonucleotide therapy market.

Leading companies in the oligonucleotide therapy market are developing advanced treatments, such as gene therapies, to target the root causes of genetic diseases, improve patient outcomes, and reduce long-term treatment burdens. Gene therapies involve introducing a functional gene into a patient's cells to replace a non-functional or mutated gene. For example, in June 2023, Sarepta Therapeutics Inc., a US-based biotechnology company, received FDA approval for ELEVIDYS, a first-of-its-kind gene therapy for ambulatory pediatric patients with Duchenne muscular dystrophy (DMD). This single-dose treatment delivers a gene coding for a shortened functional form of dystrophin to muscle cells, aiming to halt or reverse disease progression.

In April 2025, AlphaRose Therapeutics, a US-based biopharmaceutical company, acquired Alpha Anomeric SA for an undisclosed amount. This acquisition enables AlphaRose Therapeutics to strengthen its oligonucleotide therapeutics portfolio, accelerate innovation in gene-targeted therapies, expand R&D capabilities, and enhance its competitive position in the global nucleic acid therapeutics market. Alpha Anomeric SA is a France-based company specializing in oligonucleotide therapies.

Major companies operating in the oligonucleotide therapy market are Pfizer Inc., GlaxoSmithKline plc, Gilead Sciences Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Avidity Biosciences Inc., Miragen Therapeutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V., Evox Therapeutics Ltd., PepGen Ltd.

North America was the largest region in the oligonucleotide therapy market in 2025. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oligonucleotide therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oligonucleotide therapy market consists of sales of ASOs, siRNAs, miRNAs, and DNAzymes. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oligonucleotide Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses oligonucleotide therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oligonucleotide therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oligonucleotide therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Type: Antisense Oligonucleotide; Aptamer; Other Types
  • 2) By Application: Infectious Diseases; Oncology; Neurodegenerative Disorders; Cardiovascular Diseases; Kidney Diseases; Other End-User
  • 3) By End User: Hospitals; Research Institutes
  • Subsegments:
  • 1) By Antisense Oligonucleotide: RNA-Targeted Antisense Oligonucleotides; DNA-Targeted Antisense Oligonucleotides; Chemically Modified Antisense Oligonucleotides
  • 2) By Aptamer: DNA Aptamers; RNA Aptamers; Small Molecule Aptamers
  • 3) By Other Types: siRNA (Small Interfering RNA); miRNA (Micro RNA); DNAzyme And Ribozymes; Synthetic Oligonucleotides For Gene Editing
  • Companies Mentioned: Pfizer Inc.; GlaxoSmithKline plc; Gilead Sciences Inc.; Biogen Inc.; Alnylam Pharmaceuticals Inc.; Sarepta Therapeutics Inc.; Ionis Pharmaceuticals Inc.; Akcea Therapeutics Inc.; Arrowhead Pharmaceuticals Inc.; Dicerna Pharmaceuticals Inc.; SomaGenics Inc.; Wave Life Sciences Ltd.; Exicure Inc.; Avidity Biosciences Inc.; Miragen Therapeutics Inc.; ProQR Therapeutics NV; Regulus Therapeutics Inc.; Kastle Therapeutics LLC; Santaris Pharma A/S; InteRNA Technologies B.V.; Evox Therapeutics Ltd.; PepGen Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Oligonucleotide Therapy Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Oligonucleotide Therapy Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Oligonucleotide Therapy Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Oligonucleotide Therapy Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.3 Industry 4.0 & Intelligent Manufacturing
    • 4.1.4 Artificial Intelligence & Autonomous Intelligence
    • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Targeted Gene Regulation
    • 4.2.2 Rna Interference-Based Therapeutics
    • 4.2.3 Personalized Medicine Development
    • 4.2.4 Advanced Drug Delivery Systems
    • 4.2.5 Nucleic Acid-Based Diagnostics

5. Oligonucleotide Therapy Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Research Institutes
  • 5.3 Pharmaceutical Companies
  • 5.4 Biotechnology Firms
  • 5.5 Academic Institutions

6. Oligonucleotide Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Oligonucleotide Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Oligonucleotide Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Oligonucleotide Therapy Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Oligonucleotide Therapy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Oligonucleotide Therapy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Oligonucleotide Therapy Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Oligonucleotide Therapy Market Segmentation

  • 9.1. Global Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Antisense Oligonucleotide, Aptamer, Other Types
  • 9.2. Global Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Other End-User
  • 9.3. Global Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals, Research Institutes
  • 9.4. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Antisense Oligonucleotide, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • RNA-Targeted Antisense Oligonucleotides, DNA-Targeted Antisense Oligonucleotides, Chemically Modified Antisense Oligonucleotides
  • 9.5. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Aptamer, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • DNA Aptamers, RNA Aptamers, Small Molecule Aptamers
  • 9.6. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • siRNA (Small Interfering RNA), miRNA (Micro RNA), DNAzyme And Ribozymes, Synthetic Oligonucleotides For Gene Editing

10. Oligonucleotide Therapy Market Regional And Country Analysis

  • 10.1. Global Oligonucleotide Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Oligonucleotide Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Oligonucleotide Therapy Market

  • 11.1. Asia-Pacific Oligonucleotide Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Oligonucleotide Therapy Market

  • 12.1. China Oligonucleotide Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Oligonucleotide Therapy Market

  • 13.1. India Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Oligonucleotide Therapy Market

  • 14.1. Japan Oligonucleotide Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Oligonucleotide Therapy Market

  • 15.1. Australia Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Oligonucleotide Therapy Market

  • 16.1. Indonesia Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Oligonucleotide Therapy Market

  • 17.1. South Korea Oligonucleotide Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Oligonucleotide Therapy Market

  • 18.1. Taiwan Oligonucleotide Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Oligonucleotide Therapy Market

  • 19.1. South East Asia Oligonucleotide Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Oligonucleotide Therapy Market

  • 20.1. Western Europe Oligonucleotide Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Oligonucleotide Therapy Market

  • 21.1. UK Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Oligonucleotide Therapy Market

  • 22.1. Germany Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Oligonucleotide Therapy Market

  • 23.1. France Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Oligonucleotide Therapy Market

  • 24.1. Italy Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Oligonucleotide Therapy Market

  • 25.1. Spain Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Oligonucleotide Therapy Market

  • 26.1. Eastern Europe Oligonucleotide Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Oligonucleotide Therapy Market

  • 27.1. Russia Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Oligonucleotide Therapy Market

  • 28.1. North America Oligonucleotide Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Oligonucleotide Therapy Market

  • 29.1. USA Oligonucleotide Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Oligonucleotide Therapy Market

  • 30.1. Canada Oligonucleotide Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Oligonucleotide Therapy Market

  • 31.1. South America Oligonucleotide Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Oligonucleotide Therapy Market

  • 32.1. Brazil Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Oligonucleotide Therapy Market

  • 33.1. Middle East Oligonucleotide Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Oligonucleotide Therapy Market

  • 34.1. Africa Oligonucleotide Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Oligonucleotide Therapy Market Regulatory and Investment Landscape

36. Oligonucleotide Therapy Market Competitive Landscape And Company Profiles

  • 36.1. Oligonucleotide Therapy Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Oligonucleotide Therapy Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Oligonucleotide Therapy Market Company Profiles
    • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Alnylam Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Oligonucleotide Therapy Market Other Major And Innovative Companies

  • Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Avidity Biosciences Inc., Miragen Therapeutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V.

38. Global Oligonucleotide Therapy Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Oligonucleotide Therapy Market

40. Oligonucleotide Therapy Market High Potential Countries, Segments and Strategies

  • 40.1 Oligonucleotide Therapy Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Oligonucleotide Therapy Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Oligonucleotide Therapy Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer